JPS61148115A - 難溶性薬物の徐放性製剤及びその製造法 - Google Patents
難溶性薬物の徐放性製剤及びその製造法Info
- Publication number
- JPS61148115A JPS61148115A JP26859284A JP26859284A JPS61148115A JP S61148115 A JPS61148115 A JP S61148115A JP 26859284 A JP26859284 A JP 26859284A JP 26859284 A JP26859284 A JP 26859284A JP S61148115 A JPS61148115 A JP S61148115A
- Authority
- JP
- Japan
- Prior art keywords
- soluble drug
- release
- poorly soluble
- sustained release
- substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 40
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 239000003405 delayed action preparation Substances 0.000 title claims description 9
- 238000013268 sustained release Methods 0.000 claims abstract description 17
- 239000012730 sustained-release form Substances 0.000 claims abstract description 17
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002386 prazosin hydrochloride Drugs 0.000 claims abstract description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 10
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 10
- 229920001249 ethyl cellulose Polymers 0.000 claims abstract description 10
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960003883 furosemide Drugs 0.000 claims abstract description 8
- 230000008961 swelling Effects 0.000 claims abstract description 8
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 7
- 229920000642 polymer Polymers 0.000 claims abstract description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000007906 compression Methods 0.000 claims abstract description 5
- 230000006835 compression Effects 0.000 claims abstract description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 20
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- 239000001993 wax Substances 0.000 claims description 7
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 abstract description 27
- 238000002360 preparation method Methods 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 10
- 229910002651 NO3 Inorganic materials 0.000 abstract description 9
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 abstract description 9
- 238000004090 dissolution Methods 0.000 abstract description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 229920003146 methacrylic ester copolymer Polymers 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 10
- 229920002678 cellulose Polymers 0.000 description 9
- 239000001913 cellulose Substances 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 9
- 238000000748 compression moulding Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000454 talc Substances 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 235000019359 magnesium stearate Nutrition 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229910000805 Pig iron Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000012921 fluorescence analysis Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000012184 mineral wax Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012170 montan wax Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
- F04C2210/00—Fluid
- F04C2210/26—Refrigerants with particular properties, e.g. HFC-134a
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26859284A JPS61148115A (ja) | 1984-12-21 | 1984-12-21 | 難溶性薬物の徐放性製剤及びその製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26859284A JPS61148115A (ja) | 1984-12-21 | 1984-12-21 | 難溶性薬物の徐放性製剤及びその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61148115A true JPS61148115A (ja) | 1986-07-05 |
| JPH0587488B2 JPH0587488B2 (enrdf_load_stackoverflow) | 1993-12-16 |
Family
ID=17460672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP26859284A Granted JPS61148115A (ja) | 1984-12-21 | 1984-12-21 | 難溶性薬物の徐放性製剤及びその製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61148115A (enrdf_load_stackoverflow) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61286330A (ja) * | 1985-06-11 | 1986-12-16 | Teijin Ltd | 経口徐放性製剤 |
| JPS63183529A (ja) * | 1986-10-22 | 1988-07-28 | ビオメディカ・フォスカマ・インデュストリア・キミコ−ファルマチエウティカ・エッセ・ピ・ア | 放出がコントロールされた錠剤形の、ブフロメジル塩酸塩に基づく医薬調製物およびその製造方法 |
| JPH01156909A (ja) * | 1987-09-02 | 1989-06-20 | Chugai Pharmaceut Co Ltd | 持続放出製剤 |
| WO1998017271A1 (en) * | 1996-10-18 | 1998-04-30 | Euro-Celtique S.A. | Pharmaceutical composition comprising a combination of isosorbide nitrate with acetylsalicylic acid |
| JP2001354560A (ja) * | 2000-06-07 | 2001-12-25 | Toa Eiyo Ltd | イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法 |
| US6368635B1 (en) | 1991-04-19 | 2002-04-09 | Takeda Chemical Industries, Ltd. | Gastrointestinal mucosa-adherent matrixes pharmaceutical preparations and a coating composition |
| JP2005029523A (ja) * | 2003-07-09 | 2005-02-03 | Eisai Co Ltd | 新規錠剤 |
| JP2008502727A (ja) * | 2004-06-10 | 2008-01-31 | グラット エアー テクニクス インコーポレーテッド | 徐放性基材医薬品製剤 |
| JP2009501777A (ja) * | 2005-07-19 | 2009-01-22 | エティファルム | 胃保持型製剤およびそれらの製造方法 |
| JP5209966B2 (ja) * | 2005-09-01 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 崩壊性の改善された医薬組成物の製造方法 |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12226409B2 (en) | 2017-05-16 | 2025-02-18 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58109412A (ja) * | 1981-12-23 | 1983-06-29 | Toa Eiyou Kagaku Kogyo Kk | ニフエジピン固形製剤 |
-
1984
- 1984-12-21 JP JP26859284A patent/JPS61148115A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58109412A (ja) * | 1981-12-23 | 1983-06-29 | Toa Eiyou Kagaku Kogyo Kk | ニフエジピン固形製剤 |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61286330A (ja) * | 1985-06-11 | 1986-12-16 | Teijin Ltd | 経口徐放性製剤 |
| JPS63183529A (ja) * | 1986-10-22 | 1988-07-28 | ビオメディカ・フォスカマ・インデュストリア・キミコ−ファルマチエウティカ・エッセ・ピ・ア | 放出がコントロールされた錠剤形の、ブフロメジル塩酸塩に基づく医薬調製物およびその製造方法 |
| JPH01156909A (ja) * | 1987-09-02 | 1989-06-20 | Chugai Pharmaceut Co Ltd | 持続放出製剤 |
| US6368635B1 (en) | 1991-04-19 | 2002-04-09 | Takeda Chemical Industries, Ltd. | Gastrointestinal mucosa-adherent matrixes pharmaceutical preparations and a coating composition |
| WO1998017271A1 (en) * | 1996-10-18 | 1998-04-30 | Euro-Celtique S.A. | Pharmaceutical composition comprising a combination of isosorbide nitrate with acetylsalicylic acid |
| JP2001354560A (ja) * | 2000-06-07 | 2001-12-25 | Toa Eiyo Ltd | イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法 |
| JP2005029523A (ja) * | 2003-07-09 | 2005-02-03 | Eisai Co Ltd | 新規錠剤 |
| JP2008502727A (ja) * | 2004-06-10 | 2008-01-31 | グラット エアー テクニクス インコーポレーテッド | 徐放性基材医薬品製剤 |
| JP2009501777A (ja) * | 2005-07-19 | 2009-01-22 | エティファルム | 胃保持型製剤およびそれらの製造方法 |
| JP5209966B2 (ja) * | 2005-09-01 | 2013-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 崩壊性の改善された医薬組成物の製造方法 |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US11598776B2 (en) | 2011-06-03 | 2023-03-07 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| US10407393B2 (en) | 2014-08-28 | 2019-09-10 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10822307B2 (en) | 2014-08-28 | 2020-11-03 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US11186547B2 (en) | 2014-08-28 | 2021-11-30 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US10259791B2 (en) | 2014-08-28 | 2019-04-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US11090386B2 (en) | 2015-02-25 | 2021-08-17 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| US11547705B2 (en) | 2015-03-04 | 2023-01-10 | Merck Sharp & Dohme Llc | Combination of a PD-1 antagonist and a VEGF-R/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| US12083112B2 (en) | 2015-03-04 | 2024-09-10 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
| US11369623B2 (en) | 2015-06-16 | 2022-06-28 | Prism Pharma Co., Ltd. | Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor |
| US12220398B2 (en) | 2015-08-20 | 2025-02-11 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| US12226409B2 (en) | 2017-05-16 | 2025-02-18 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0587488B2 (enrdf_load_stackoverflow) | 1993-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61148115A (ja) | 難溶性薬物の徐放性製剤及びその製造法 | |
| US4772475A (en) | Controlled-release multiple units pharmaceutical formulation | |
| RU2245148C2 (ru) | Фармацевтическая композиция на основе месалазина для перорального введения с регулируемым высвобождением активного ингредиента | |
| JP4077886B2 (ja) | 不溶性薬剤の持効性ヘテロ分散ヒドロゲル系 | |
| JPS6230709A (ja) | 持続性製剤 | |
| JPH0122245B2 (enrdf_load_stackoverflow) | ||
| US20020054911A1 (en) | Novel oral dosage form for carvedilol | |
| CZ2001215A3 (cs) | Entericky povlečená farmaceutická tableta a způsob její přípravy | |
| MXPA03009588A (es) | Un recubrimiento novedoso para una composicion farmaceutica de liberacion sostenida. | |
| JPS6124516A (ja) | 持続性錠剤 | |
| WO2000024423A1 (fr) | Particules a liberation prolongee | |
| JPH0761922A (ja) | 放出開始制御型製剤 | |
| JPH03184911A (ja) | 錠剤にした経口的投与単位形態の球状顆粒からの制御された解放の製剤学的組成物 | |
| JPH05221854A (ja) | 水溶性薬物を含有する制御的放出錠剤 | |
| JPS6248618A (ja) | 徐放性製剤およびその製造法 | |
| US5234691A (en) | Sustained-release prepararation of basic medical agent hydrochloride | |
| WO2002043706A9 (en) | Prolamin-based sustained-release compositions and delayed-onset compositions | |
| US20010001658A1 (en) | Granule modulating hydrogel system | |
| JPS63146816A (ja) | レイン誘導体の経口用遅延放出性薬剤 | |
| AU751117B2 (en) | Novel oral dosage form for carvedilol | |
| JPH0624991A (ja) | ウルソデスオキシコール酸持続性製剤 | |
| JP7650033B2 (ja) | ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用 | |
| TWI745598B (zh) | 非布司他控釋組合物及其製備方法 | |
| JPS6087216A (ja) | 一定放出性固体投薬形インドメタシン組成物および関節炎その他の炎症性状態の治療法 | |
| JPS6133007B2 (enrdf_load_stackoverflow) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |